High Frequency of Human Papillomavirus Type 53 in Oral Cavity of Asymptomatic HIV-Infected People

In this way, we conducted a descriptive, case–control study in 197 individuals aged from 18 to 75 years and asymptomatic for oral lesions. The target group consisted of 77 HIV-positive individuals who attended at the University Hospital's ambulatory, Niterói City, Rio de Janeiro, Brazil, between 2009 and 2010. The control group included 120 volunteers from University Hospital's blood donors service, located in the same city. The Ethics Committee of the College of Medicine of the University provided ethical clearance for the protocol and informed consent, under the registration 357.085. Demographic and behavioral data were collected through a structured questionnaire. For HIV-positive people, CD4 counts were determined and plasma HIV-1 RNA levels were measured. An oral mucosal sample was harvested from all participants. The DNA extracted was submitted to PCR assay for HPV detection using MY09/11 consensus primers and HPV positive samples were typified by restriction fragment length polymorphism analysis (RFLP) or automated sequencing. A databank was generated in the SPSS-18 statistical packet to identify associations between variants and the presence of HPV.

Regarding HIV infection status, 68.4% of patients had undetectable HIV viral load, 76.6% reported HIV diagnostic more than 4 four years prior, and 88.3% were undergoing antiviral therapy. At the time of our study, 90.9% of patients had above 200 CD4+ cells/mL. Demographic variables did not affect HPV infection in HIV positive or negative people. However, oral HPV infection was significantly associated with HIV-positive individuals (59.7% versus 38.3%, p = 0.004). Table 1 displays the spectrum of HPV genotypes found in oral cavity from both populations. They are categorized according to the criterion based on the risk for cervical cancer...²

Table 1.

Occurrence of oral HPV genotypes in HIV-positive and negative people.

HPV genotypes	HPV genotypes frequency		Odds ratio (95% CI)	χ2
	HIV+ N (%)	HIV− N (%)		p-Value
Low risk
6	11 (14.3)	33 (27.5)	0.43 (0.20–0.93)	0.021
11	6 (7.8)	0.0	1.08 (1.01–1.15)	0.003
13	1 (1.3)	0.0
72	0.0	1 (0.8)
High risk
18	1 (1.3)	1 (0.8)
52	0.0	1 (0.8)
Probable high risk
53	17 (22.1)	1 (0.8)	33.72 (4.38–259.4)	0.000
82	2 (2.6)	0.0
Undetermined risk
32	0.0	1 (0.8)
71	0.0	2 (1.7)
84	0.0	1 (0.8)
Beta-papillomavirus
110	1 (1.3)	0.0
120	2 (2.6)	0.0
Co-infections	15 (89.1)	5 (10.9)	3.96 (1.30–12.09)	0.021
Unidentified types	20 (26.0)	11 (9.2)	3.47 (1.55–7.75)	0.002
Negative samples	31 (40.3)	74 (61.7)

Full article at:   http://goo.gl/WgjIZw

By:   Silva CO¹, Santos LS¹, Pereira OM², Azevedo KM³, Oliveira LH⁴.

¹Department of Microbiology and Parasitology, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil.

²Blood Bank of University Hospital, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil.

³Infectious and Parasitic Diseases Service, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil.

⁴Department of Microbiology and Parasitology, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil. Electronic address: virologia.uff@gmail.com.

  

More at:  https://twitter.com/hiv insight

And: http://twitter.com/Prison Health